Merck: All Eyes On Key Clinical Catalyst In March


  • Merck is an American biopharma powerhouse that has generated consistent compounding growth, increasing its top line and EPS.
  • Merck expects to deploy capital through strategic small bolt-on acquisitions, which we are a big fan of, rather than rampant big indiscriminate acquisitions.
  • Merck’s late-stage candidate Sotatercept and MK-0616’s clinical data are expected to be presented during March’s ACC conference; we expect the results to be positive.
  • We initiate Merck with a Buy rating.
Young female scientist working in laboratory


Company background

Merck & Co (NYSE:MRK) is an American big pharmaceutical company also known as MSD, outside of the United States and Canada. Merck is a global pharmaceutical company that develops, manufactures, and sells a wide range of healthcare products. The company was founded in

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Biotechvalley Insights (BTVI) is not a registered investment advisor, and articles are not targeted toward retail investors. The content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in our articles or comments constitutes a solicitation, recommendation, endorsement, or offer by Biotechvalley Insights or any third-party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction.

The research and reports made available by BTVI reflect and express the opinion of the applicable BTVI entity as of the time of the report only. Reports are based on generally-available information, field research, inferences, and deductions through the applicable due diligence and analytical process. BTVI may use resources from brokerage reports, corporate IR, and KOL/expert interviews that may have a conflict of interest with the company/assets that BTVI covers. To the best of the applicable BTVI’s ability and belief, all information contained herein is accurate and reliable, is not material non-public information, and has been obtained from public sources that the applicable BTVI entity believes to be accurate and reliable. However, such information is presented “as is” without warranty of any kind, whether express or implied. With respect to their respective research reports, BTVI makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. Further, any analysis/comment contains a very large measure of analysis and opinion. All expressions of opinion are subject to change without notice, and BTVI does not undertake to update or supplement any reports or any of the information, analysis, and opinion contained in them.

Leave a Reply

Your email address will not be published. Required fields are marked *